Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
22 5월 2023 - 8:00PM
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage
biopharmaceutical company focused on developing small molecules to
restore neuronal health and slow neurodegeneration, today announced
the appointment of Andrew Gengos as Chief Financial Officer and
Chief Business Officer, effective immediately. Mr. Gengos replaces
Glenna Mileson, who is retiring after serving as Athira’s Chief
Financial Officer for eight years.
“On behalf of the entire Athira team, we thank Glenna for her
many years of service, particularly for her stewardship during our
transition to a publicly traded company, and wish her well in
retirement,” said Mark Litton, Ph.D., President and Chief Executive
Officer, Athira Pharma.
“We are delighted to welcome Andrew to the Athira team and look
forward to his leadership as we continue to advance our goal to
make a significant impact on neurodegenerative diseases,” said Dr.
Litton. “Andrew’s broad experience in finance, corporate strategy,
fundraising transactions and business development will be of great
value as we strive to build Athira into a leading neuronal health
company.”
“I’m excited to join Athira at this important time as the
growing body of preclinical and clinical data continues to support
the therapeutic potential of enhancing the HGF/MET system to
protect and repair neuronal networks in neurodegenerative diseases
such as Alzheimer’s, Parkinson’s and ALS,” said Mr. Gengos. “It’s
an honor to be part of this highly talented and dedicated team
committed to developing new treatments to improve the lives of
patients suffering from neurodegenerative diseases.”
Mr. Gengos is a seasoned finance and corporate strategy
executive with more than 30 years of experience successfully
leading teams in the life sciences and biotechnology industry. Most
recently, he served as the Chief Business Officer at Cyteir
Therapeutics, where he was an integral part of the leadership team
that took the company public. Prior to that, Mr. Gengos held Chief
Executive Officer roles at ImmunoCellular Therapeutics and
Neuraltus Pharmaceuticals, where he provided strategic and
financial leadership across multiple therapeutic areas, including
oncology and neurodegenerative disease. In addition to these
leadership positions, Mr. Gengos also held the Chief Financial
Officer and Chief Business Officer roles at AOBiome Therapeutics
and was the Chief Operating Officer and Head of Corporate
Development at Synlogic, Inc. Earlier, Mr. Gengos was Vice
President of Strategy and Corporate Development at Amgen for eight
years. Mr. Gengos started his career as a Technology Associate at
Morgan Stanley before moving on to McKinsey & Co., where he
advanced from associate to Senior Engagement Manager, focusing in
the Healthcare and Strategy practices. Mr. Gengos holds a Master of
Business Administration from the UCLA Anderson School of Management
and a Bachelor of Science in Chemical Engineering from the
Massachusetts Institute of Technology.
About Athira Pharma, Inc.Athira Pharma, Inc.,
headquartered in the Seattle, Washington area, is a late
clinical-stage biopharmaceutical company focused on developing
small molecules to restore neuronal health and slow
neurodegeneration. Athira aims to provide rapid cognitive
improvement and alter the course of neurological diseases with its
novel mechanism of action. Athira is currently advancing its
pipeline of therapeutic candidates targeting the HGF/MET
neurotrophic system for Alzheimer’s and Parkinson’s disease,
Dementia with Lewy bodies and amyotrophic lateral sclerosis (ALS).
For more information, visit www.athira.com. You can also
follow Athira on Facebook, LinkedIn, Twitter and
@athirapharma on Instagram.
Forward-Looking StatementsThis communication
contains “forward-looking statements” within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are not based on
historical fact and include statements regarding: product
candidates as a potential treatment for Alzheimer’s disease,
Parkinson’s disease dementia, Dementia with Lewy bodies,
neuropsychiatric diseases, and other neurodegenerative diseases,
such as amyotrophic lateral sclerosis; Athira’s platform technology
and potential therapies; future development plans;; expectations
regarding the safety, potential efficacy and commercial potential
of Athira’s product candidates; ; and Athira’s ability to advance
its product candidates into later stages of development.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as “may,” “will,” “should,” “on
track,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,”
“continue,” “suggest,” “potential,” and other similar expressions,
among others. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the data for our
product candidates from our preclinical and clinical trials not
supporting the safety, efficacy and tolerability of our product
candidates; cessation or delay of Athira’s development of product
candidates may occur; regulatory authorities could object to
protocols, amendments and other submissions; future potential
regulatory milestones for product candidates, including those
related to current and planned clinical studies, may be
insufficient to support regulatory submissions or approval; the
impact of the COVID-19 pandemic on Athira’s business, research and
clinical development plans and timelines, and the regulatory
process for Athira product candidates; Athira may not be able to
recruit sufficient patients for its clinical trials; the
outcome of legal proceedings that have been or may in the future be
instituted against us and certain of our directors and officers;
clinical trials may not demonstrate safety and efficacy of any of
Athira’s product candidates; possible negative interactions of
Athira's product candidates with other treatments; Athira’s
assumptions regarding the sufficiency of its cash, cash equivalents
and investments to fund its planned operations may be incorrect;
adverse conditions in the general domestic and global economic
markets; the impact of competition; regulatory agencies may be
delayed in reviewing, commenting on or approving any of Athira’s
clinical development plans as a result of the COVID-19 pandemic,
which could further delay development timelines; the impact of
expanded product development and clinical activities on operating
expenses; the impact of new or changing laws and regulations; as
well as the other risks detailed in Athira’s filings with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof and Athira undertakes
no obligation to update forward-looking statements. Athira may not
actually achieve the plans, intentions, or expectations disclosed
in its forward-looking statements, and you should not place undue
reliance on the forward-looking statements.
Investor & Media Contact:
Julie RathbunAthira
PharmaJulie.rathbun@athira.com206-769-9219
Athira Pharma (NASDAQ:ATHA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Athira Pharma (NASDAQ:ATHA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024